<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The development of effective therapies for the prevention of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> is of great importance </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, <z:chebi fb="0" ids="16261">chitosan</z:chebi> (CS) nanoparticles have been utilized as carriers of interluekin-12 (IL-12) administered locally to deliver therapeutic proteins and genes </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we encapsulated IL-12 by incorporation using tripolyphosphate (<z:chebi fb="2" ids="35033,52279,9532">TPP</z:chebi>) as the coacervated crosslinking agent to form CS-<z:chebi fb="2" ids="35033,52279,9532">TPP</z:chebi>/IL-12 nanoparticles </plain></SENT>
<SENT sid="3" pm="."><plain>We further characterized the association efficiency, rate of release, liver-targeting, and toxicity, which were predominantly dependent on the factors of particle size, zeta potential, pH of solution, and whether or not modified with <z:chebi fb="2" ids="35033,52279,9532">TPP</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Systemic delivery of CS-<z:chebi fb="2" ids="35033,52279,9532">TPP</z:chebi>/IL-12 nanoparticles significantly reduced the number and volume of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> foci compared to the CS-<z:chebi fb="2" ids="35033,52279,9532">TPP</z:chebi> treated mouse group </plain></SENT>
<SENT sid="5" pm="."><plain>Although delivery of IL-12 alone also inhibited the number of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> observed, further study of the change in <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> volume demonstrated no significant differences between the groups treated with CS-<z:chebi fb="2" ids="35033,52279,9532">TPP</z:chebi> or IL-12 alone </plain></SENT>
<SENT sid="6" pm="."><plain>Mechanistically, CS-<z:chebi fb="2" ids="35033,52279,9532">TPP</z:chebi> nanoparticles blocked the toxicity of IL-12 and induced infiltration of NK cells and some T cells, which are most likely the effector cells that mediate <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumor metastasis</z:e> inhibition during CS-<z:chebi fb="2" ids="35033,52279,9532">TPP</z:chebi>/IL-12 immunotherapy </plain></SENT>
<SENT sid="7" pm="."><plain>The results obtained from this study demonstrate the potential benefit of using <z:chebi fb="0" ids="16261">chitosan</z:chebi> modification technology as a cytokine delivery system for the successful prevention of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> by exploiting liver immunity </plain></SENT>
</text></document>